Key facts
- Reperio’s last known valuation is $60.0M (May 2025).
- It has raised $32.0M; the latest was Seed Round ($14.0M) in May 2025.
- Notable investors include Liquid 2 Ventures, Portland Seed Fund, G Ventures (VC), Caduceus Capital Partners, Rogue Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Reperio
- ·The full record, as it builds
Funding rounds
No funding rounds for Reperio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reperio
Developer of an at-home health assessment platform designed for preventive care. The company's platform collects multiple health metrics in real-time, including blood pressure, resting heart rate, body mass index, relative fat mass, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and glucose levels, enabling individuals to monitor their health conveniently while ensuring accessibility to essential health information with AI-assisted virtual visit with a licensed medical professional.
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2020
- Employees
- 25
- Website
- reperiohealth.com/
- Ownership
- Privately Held (backing)
Reperio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reperio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reperio in its N-PORT filings yet. We sweep new filings monthly.